Literature DB >> 32101639

Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease.

Vasiliki Orgeta1, Kathryn R McDonald2, Ellen Poliakoff3, John Vincent Hindle4, Linda Clare5, Iracema Leroi6.   

Abstract

BACKGROUND: Approximately 60% to 80% of people with Parkinson's disease (PD) experience cognitive impairment that impacts on their quality of life. Cognitive decline is a core feature of the disease and can often present before the onset of motor symptoms. Cognitive training may be a useful non-pharmacological intervention that could help to maintain or improve cognition and quality of life for people with PD dementia (PDD) or PD-related mild cognitive impairment (PD-MCI).
OBJECTIVES: To determine whether cognitive training (targeting single or multiple domains) improves cognition in people with PDD and PD-MCI or other clearly defined forms of cognitive impairment in people with PD. SEARCH
METHODS: We searched the Cochrane Dementia and Cognitive Improvement Group Trials Register (8 August 2019), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, and PsycINFO. We searched reference lists and trial registers, searched relevant reviews in the area and conference proceedings. We also contacted experts for clarifications on data and ongoing trials. SELECTION CRITERIA: We included randomised controlled trials where the participants had PDD or PD-MCI, and where the intervention was intended to train general or specific areas of cognitive function, targeting either a single domain or multiple domains of cognition, and was compared to a control condition. Multicomponent interventions that also included motor or other elements were considered eligible. DATA COLLECTION AND ANALYSIS: Two review authors independently screened titles, abstracts, and full-text articles for inclusion in the review. Two review authors also independently undertook extraction of data and assessment of methodological quality. We used GRADE methods to assess the overall quality of the evidence. MAIN
RESULTS: Seven studies with a total of 225 participants met the inclusion criteria for this review. All seven studies compared the effects of a cognitive training intervention to a control intervention at the end of treatment periods lasting four to eight weeks. Six studies included people with PD living in the community. These six studies recruited people with single-domain (executive) or multiple-domain mild cognitive impairment in PD. Four of these studies identified participants with MCI using established diagnostic criteria, and two included both people with PD-MCI and people with PD who were not cognitively impaired. One study recruited people with a diagnosis of PD dementia who were living in long-term care settings. The cognitive training intervention in three studies targeted a single cognitive domain, whilst in four studies multiple domains of cognitive function were targeted. The comparison groups either received no intervention or took part in recreational activities (sports, music, arts), speech or language exercises, computerised motor therapy, or motor rehabilitation combined with recreational activity. We found no clear evidence that cognitive training improved global cognition. Although cognitive training was associated with higher scores on global cognition at the end of treatment, the result was imprecise and not statistically significant (6 trials, 178 participants, standardised mean difference (SMD) 0.28, 95% confidence interval (CI) -0.03 to 0.59; low-certainty evidence). There was no evidence of a difference at the end of treatment between cognitive training and control interventions on executive function (5 trials, 112 participants; SMD 0.10, 95% CI -0.28 to 0.48; low-certainty evidence) or visual processing (3 trials, 64 participants; SMD 0.30, 95% CI -0.21 to 0.81; low-certainty evidence). The evidence favoured the cognitive training group on attention (5 trials, 160 participants; SMD 0.36, 95% CI 0.03 to 0.68; low-certainty evidence) and verbal memory (5 trials, 160 participants; SMD 0.37, 95% CI 0.04 to 0.69; low-certainty evidence), but these effects were less certain in sensitivity analyses that excluded a study in which only a minority of the sample were cognitively impaired. There was no evidence of differences between treatment and control groups in activities of daily living (3 trials, 67 participants; SMD 0.03, 95% CI -0.47 to 0.53; low-certainty evidence) or quality of life (5 trials, 147 participants; SMD -0.01, 95% CI -0.35 to 0.33; low-certainty evidence). There was very little information on adverse events. We considered the certainty of the evidence for all outcomes to be low due to risk of bias in the included studies and imprecision of the results. We identified six ongoing trials recruiting participants with PD-MCI, but no ongoing trials of cognitive training for people with PDD. AUTHORS'
CONCLUSIONS: This review found no evidence that people with PD-MCI or PDD who receive cognitive training for four to eight weeks experience any important cognitive improvements at the end of training. However, this conclusion was based on a small number of studies with few participants, limitations of study design and execution, and imprecise results. There is a need for more robust, adequately powered studies of cognitive training before conclusions can be drawn about the effectiveness of cognitive training for people with PDD and PD-MCI. Studies should use formal criteria to diagnose cognitive impairments, and there is a particular need for more studies testing the efficacy of cognitive training in people with PDD.
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2020        PMID: 32101639      PMCID: PMC7043362          DOI: 10.1002/14651858.CD011961.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  146 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Randomized controlled trial of memantine in dementia associated with Parkinson's disease.

Authors:  Iracema Leroi; Ross Overshott; E Jane Byrne; Emily Daniel; Alistair Burns
Journal:  Mov Disord       Date:  2009-06-15       Impact factor: 10.338

3.  Can individual home-based cognitive stimulation therapy benefit Parkinson's patients with mild to moderate cognitive impairment?

Authors:  Farheen Farzana; Vemula Sreekanth; Mohammed Khaliq Mohiuddin; Vasavi Mohan; N Balakrishna; Y R Ahuja
Journal:  Int J Geriatr Psychiatry       Date:  2015-04       Impact factor: 3.485

Review 4.  Cognitive interventions in healthy older adults and people with mild cognitive impairment: a systematic review.

Authors:  Jennifer Reijnders; Caroline van Heugten; Martin van Boxtel
Journal:  Ageing Res Rev       Date:  2012-07-25       Impact factor: 10.895

Review 5.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia.

Authors:  P S Mathuranath; P J Nestor; G E Berrios; W Rakowicz; J R Hodges
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

7.  Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis.

Authors:  Lars Bäckman; Sari Jones; Anna-Karin Berger; Erika Jonsson Laukka; Brent J Small
Journal:  Neuropsychology       Date:  2005-07       Impact factor: 3.295

Review 8.  Dementia associated with Parkinson's disease.

Authors:  Murat Emre
Journal:  Lancet Neurol       Date:  2003-04       Impact factor: 44.182

9.  Cognitive rehabilitation in Parkinson's disease: evidence from neuroimaging.

Authors:  Cristina Nombela; Pedro J Bustillo; Pedro F Castell; Lucía Sanchez; Vicente Medina; María Trinidad Herrero
Journal:  Front Neurol       Date:  2011-12-22       Impact factor: 4.003

10.  Cognitive impairment and dementia in Parkinson's disease: clinical features, diagnosis, and management.

Authors:  Joana Meireles; João Massano
Journal:  Front Neurol       Date:  2012-05-25       Impact factor: 4.003

View more
  19 in total

Review 1.  The Impact of COVID-19 Infection on Cognitive Function and the Implication for Rehabilitation: A Systematic Review and Meta-Analysis.

Authors:  Sarah Houben; Bruno Bonnechère
Journal:  Int J Environ Res Public Health       Date:  2022-06-24       Impact factor: 4.614

2.  Oral Administration of Silibinin Ameliorates Cognitive Deficits of Parkinson's Disease Mouse Model by Restoring Mitochondrial Disorders in Hippocampus.

Authors:  Xiumin Liu; Chenkang Wang; Weiwei Liu; Siaoyu Song; Jianing Fu; Toshihiko Hayashi; Kazunori Mizuno; Shunji Hattori; Hitomi Fujisaki; Takashi Ikejima
Journal:  Neurochem Res       Date:  2021-06-07       Impact factor: 3.996

Review 3.  Parkinson disease-associated cognitive impairment.

Authors:  Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub
Journal:  Nat Rev Dis Primers       Date:  2021-07-01       Impact factor: 52.329

4.  Enhancement of Executive Functions but Not Memory by Multidomain Group Cognitive Training in Patients with Parkinson's Disease and Mild Cognitive Impairment: A Multicenter Randomized Controlled Trial.

Authors:  Elke Kalbe; Ann-Kristin Folkerts; Anja Ophey; Carsten Eggers; Saskia Elben; Karina Dimenshteyn; Patricia Sulzer; Claudia Schulte; Nele Schmidt; Christian Schlenstedt; Daniela Berg; Karsten Witt; Lars Wojtecki; Inga Liepelt-Scarfone
Journal:  Parkinsons Dis       Date:  2020-11-30

5.  Computerised cognitive training in Parkinson's disease: a protocol for a systematic review and updated meta-analysis.

Authors:  Hanna Malmberg Gavelin; Magdalena Domellöf; Isabella Leung; Anna Stigsdotter Neely; Carsten Finke; Amit Lampit
Journal:  BMJ Open       Date:  2020-11-24       Impact factor: 2.692

6.  Memory enhancement by multidomain group cognitive training in patients with Parkinson's disease and mild cognitive impairment: long-term effects of a multicenter randomized controlled trial.

Authors:  Elke Kalbe; Karsten Witt; Nele Schmidt; Inken Tödt; Daniela Berg; Christian Schlenstedt; Ann-Kristin Folkerts; Anja Ophey; Karina Dimenshteyn; Saskia Elben; Lars Wojtecki; Inga Liepelt-Scarfone; Claudia Schulte; Patricia Sulzer; Carsten Eggers
Journal:  J Neurol       Date:  2021-04-27       Impact factor: 6.682

Review 7.  Approach to Cognitive Impairment in Parkinson's Disease.

Authors:  Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 6.088

8.  Evaluating a frontostriatal working-memory updating-training paradigm in Parkinson's disease: the iPARK trial, a double-blinded randomized controlled trial.

Authors:  Magdalena Eriksson Domellöf; Lois Walton; Carl-Johan Boraxbekk; David Bäckström; Maria Josefsson; Lars Forsgren; Anna Stigsdotter Neely
Journal:  BMC Neurol       Date:  2020-09-07       Impact factor: 2.474

9.  Effectiveness of Cognitive Rehabilitation in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Itsasne Sanchez-Luengos; Yolanda Balboa-Bandeira; Olaia Lucas-Jiménez; Natalia Ojeda; Javier Peña; Naroa Ibarretxe-Bilbao
Journal:  J Pers Med       Date:  2021-05-18

10.  Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinson's disease.

Authors:  Saul Martínez-Horta; Helena Bejr-Kasem; Andrea Horta-Barba; Berta Pascual-Sedano; Diego Santos-García; Teresa de Deus-Fonticoba; Silvia Jesús; Miquel Aguilar; Lluis Planellas; Juan García-Caldentey; Nuria Caballol; Bárbara Vives-Pastor; Jorge Hernández-Vara; Iria Cabo-Lopez; Lydia López-Manzanares; Isabel González-Aramburu; Maria Asunción Ávila-Rivera; Maria Jose Catalán; Luis Manuel López-Díaz; Victor Puente; Jose Manuel García-Moreno; Carmen Borrué; Berta Solano-Vila; Maria Álvarez-Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo-Padilla; Juan Carlos Martínez-Castrillo; Pilar Sánchez-Alonso; Maria Gema Alonso-Losada; Nuria López-Ariztegui; Itziar Gastón; Marta Blázquez-Estrada; Manual Seijo-Martínez; Javier Rúiz-Martínez; Caridad Valero-Merino; Monica Kurtis; Oriol de Fábregues-Boixar; Jessica González-Ardura; Cristina Prieto-Jurczynska; Pablo Martinez-Martin; Pablo Mir; Jaime Kulisevsky
Journal:  BMC Neurol       Date:  2021-12-08       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.